Open-House Biologics Discount Agreements 2025-20 - Pegfilgrastim
Original notice title
Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
40 / 100
Risk factors
The procedure is explicitly not a public procurement under EU directives; therefore, standard procurement remedies are...
Open House allows any eligible participant, potentially resulting in many competitors and high price pressure.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Aug 2027
- Conclusion of pharmaceutical discount agreements for Pegfilgrastim under §130a(8) SGB V.
- Open-House procedure: any eligible pharmaceutical entrepreneur can participate.
Show full summary
Open House procedure for concluding discount agreements (Rabattverträge) under §130a(8) SGB V for the active substance Pegfilgrastim. Any qualified pharmaceutical entrepreneur can join during the contract period (01.09.2025 – 31.08.2027). No exclusivity, no negotiated terms; uniform conditions apply.
Risks
The procedure is explicitly not a public procurement under EU directives; therefore, standard procurement remedies are...
Open House allows any eligible participant, potentially resulting in many competitors and high price pressure.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur according to §4(18) AMG regarding the offered medicinal product.
- Must have a valid marketing authorization for the drug (§21 AMG) or be otherwise entitled to market it.
- Seat must be in Germany, another EU member state, or an EEA state.
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open-House Biologics Discount Agreements 2025-20 - Pegfilgrastim
Conclusion of discount agreements for the active substance Pegfilgrastim via Open-House procedure. Open to all eligible pharmaceutical entrepreneurs during the contract period.
Location
Duration
Category
Deadline
Award details
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Pegfilgrastim im Rahmen eines Open-House-Verfahrens.
Value note
Show original TED data
Original lot title
Open-House-Biologika-Rabattverträge 2025-20 - Pegfilgrastim
Original TED description
Ziel ist der Abschluss von Arzneimittelrabattverträgen nach § 130a Abs. 8 SGB V zu dem Wirkstoff Pegfilgrastim im Rahmen eines Open-House-Verfahrens.
Procurement Details
- Publication date
- 16 Jul 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 468072-2025
Documents (1)
Similar tenders
Germany – Site preparation work – VE111 Baustelleneinrichtung (119VM514 / Kronsh,SanDstBw,Ersatzneub. ZInstSanBw)
Poland – Advertising and marketing services – Zaplanowanie i realizacja kampanii Ministerstwa Finansów z zakresu działalności resortu finansów
France – Insurance services – Prestations de services d'assurance pour groupement le groupement hospitalier de territoire Yvelines Nord
Finland – Architectural, construction, engineering and inspection services – Tietomallikoordinaattori-, inventointimittaus- ja mallinnuspalvelujen puitejärjestely 2026-2028 (2028-2030)
Greece – Cultural event organisation services – ΛΕΙΤΟΥΡΓΙΑ ΤΟΥ ΘΕΑΤΡΟΥ ΟΛΥΜΠΙΑ ΜΑΡΙΑ ΚΑΛΛΑΣ ΜΕ ΕΞΕΙΔΙΚΕΥΜΕΝΟ ΠΡΟΣΩΠΙΚΟ
Spain – Architectural, construction, engineering and inspection services – Redacción del Proyecto Básico y de Ejecución, Redacción del Estudio de Seguridad y Salud y Dirección de Obra para la construcción del I.E.S. Nº 1 de 12+0 uds. (Fase 1) en la urbanización El Bosque de Pioz (Guadalajara).
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
40 / 100
Risk factors
The procedure is explicitly not a public procurement under EU directives; therefore, standard procurement remedies are...
Open House allows any eligible participant, potentially resulting in many competitors and high price pressure.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications